Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health
Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005217/en/
Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health (Photo: Business Wire)
BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals A/S (Ferring) have expanded their collaboration with the objective to accelerate world-class life science innovation within women’s health. New activities will include supporting BII to source, and potentially fund and incubate early-stage start-ups and projects within the field of reproductive medicine.
“The new strategic collaboration, highlights Ferring’s continued commitment to invest in early-stage innovation in this area, and we look forward to strengthening our collaboration with BII to accelerate new solutions for patients,” says Armin Metzger, Executive Vice President and Chief Science Officer at Ferring.
The strategic collaboration builds on Ferring’s engagement with BII’s Women’s Health Initiative through Ferring’s membership on the BII Women’s Health Innovation Panel. Women’s health is underserved as only 1% of global healthcare research funding is invested in female-specific conditions beyond oncology.1 The collaboration aims to bridge the gap by supporting early-stage innovation and will leverage BII’s proven expertise in translational science incubation, together with Ferring’s expertise in early-stage development and reproductive medicine.
“Combining BII’s already proven incubation expertise with the industrial expertise and deep insights that Ferring has within women’s health forms a very strong basis for supporting and accelerating our mission of getting more solutions on the market that address the high unmet needs of 50% of the world’s population. We are pleased to collaborate even closer with Ferring to make it happen,” says Trine Bartholdy, Chief Innovation Officer at the BioInnovation Institute.
About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries.
Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, Facebook, Twitter and YouTube.
The BioInnovation Institute Foundation:
At BioInnovation Institute (BII), we accelerate world-class life science start-up innovation for the benefit of people and society. As a non-profit institute, BII operates the company creation programs, Bio Studio, Venture Lab and Venture House, to support life science start-ups with knowledge, network, infrastructure and funding of up to EUR 3 million per project and EUR 1,8 million per start-up. With our expertise, network, funding, and infrastructure, we empower start-ups to succeed and believe in the transformative power of life science innovation. Read more on www.bioinnovationinstitute.com.
1 McKinsey & Company. Unlocking opportunities in women’s healthcare. 2022. Available at: https://www.mckinsey.com/industries/healthcare/our-insights/unlocking-opportunities-in-womens-healthcare [Last accessed April 2023]
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005217/en/
Contact information
For more information, please contact:
Ferring Pharmaceuticals
Björn Lindström
Director, Corporate Communications & Public Affairs
+45 28 78 78 62
Bjoern.lindstroem@ferring.com
BioInnovation Institute
Casper Linnemann
Head of Communication
+45 4172 7994
cli@bii.dk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armis Launches New Partner Program, Expanding its Reach to Help Global Organizations Enhance Cyber Resilience14.1.2026 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced the launch of the Armis Select Partner Program. The new program marks a significant evolution in Armis' commitment to its global partner ecosystem. By extending the reach of Armis Centrix™, the Armis Cyber Exposure Management Platform, to organizations worldwide through its partner program, joint customers can streamline their security operations and proactively strengthen defenses. “Global enterprises don’t just need tools; they need a unified ecosystem of trusted partners to navigate an increasingly volatile threat landscape,” said Alex Mosher, President and CRO of Armis. “At Armis, our partners are the primary engine of our growth and the cornerstone of our global strategy. By evolving our partner program, we are doubling down on this collaborative foundation to accelerate our reach and deepen our impact. Together, we are empowering customers to move from reactive defense to proactive cyber exposure management
Rapyd’s 2026 State of Stablecoins: Businesses Move En Masse as Stablecoins Go Mainstream14.1.2026 15:00:00 EET | Press release
Rapyd, a leading global fintech company, released its 2026 State of Stablecoins Report, revealing that stablecoins have reached a tipping point and are becoming a foundational component of global commerce rather than a niche digital asset. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114427729/en/ Rapyd research shows 64% of businesses already use stablecoins or plan to within three years, as speed, cross-border efficiency, and cost savings drive mainstream adoption. The report shows the market has moved decisively into active, real-world use. Today, nearly one in five businesses already consider stablecoins a mainstream financial tool. Looking ahead, a much larger majority (76%) believe stablecoins are either already mainstream or will become mainstream within the next five years. This shift in perception is translating into action: 64% of businesses surveyed either use stablecoins today or plan to adopt them within th
WEP Clinical Acquires Netherlands-Based CRO Siron Clinical, Expanding Global Phase I–IV Trial Delivery Capabilities14.1.2026 15:00:00 EET | Press release
WEP Clinical (WEP), a full-service contract research organization (CRO), announces the acquisition of Siron Clinical (Siron), a Netherlands-based European CRO specializing in flexible, high-quality clinical operations for biotech companies. The acquisition expands WEP’s global footprint and strengthens its ability to deliver end-to-end Phase I–IV clinical trial solutions across complex, rare, and specialized therapeutic areas. Founded in 2000, Siron is headquartered in the Netherlands, with additional offices in Belgium and Germany, and clinical research professionals based across Europe and the Middle East. The company specializes in clinical operations, including project management, clinical monitoring, quality assurance, and regulatory submissions. Siron has supported more than 120 studies and has a strong track record in orphan diseases, pediatric research, and medical device trials. Jaswinder Khera, WEP Founder and CEO, said: “This acquisition represents a significant milestone in
Alpaca Raises $150 Million at a $1.15B Valuation to Build the Global Standard for Brokerage Infrastructure14.1.2026 14:00:00 EET | Press release
Alpaca, a global leader in brokerage infrastructure whose APIs empower partners like Kraken, SBI Securities, and Dime!, today announced it has raised a $150 million Series D led by Drive Capital that values the company at $1.15 billion. Drive Capital’s Co-Founder and Partner, Chris Olsen, will join Alpaca’s Board of Directors as part of the investment. The company also secured a $40 million line of credit, further strengthening its balance sheet as it continues to expand globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114225657/en/ Alpaca Raises $150 Million at a $1.15B Valuation to Build the Global Standard for Brokerage Infrastructure “Our mission is to open financial services to everyone on the planet,” said Yoshi Yokokawa, Co-Founder and CEO of Alpaca. “We are building the global standard for brokerage infrastructure so our partners can bring investing to more people. This raise gives us the fuel to deliver m
Sixth Street Raises €3.75 Billion for Third European Direct Lending Fund14.1.2026 13:30:00 EET | Press release
Sixth Street, a leading global investment firm, today announced the final close of Sixth Street Specialty Lending Europe III (“SLE III” or “the Fund”), at its hard cap with €3.75 billion in total equity commitments. SLE III is Sixth Street’s third and largest dedicated fund focused on providing financing solutions for companies across Europe. The total investable capital for SLE III is expected to be approximately €7 billion, including anticipated leverage. “We are grateful to our long-term capital partners for their trust and commitment to our strategy as we continue to support European businesses at any point in their lifecycle, offering customized capital solutions delivered with speed and certainty,” said Michael Griffin, Co-Head of Sixth Street Global Direct Lending and Head of Europe Direct Lending. “This is a significant milestone for our European Direct Lending business and a testament to the firm’s intentional growth in the region. While Sixth Street has spent the past two dec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom